Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 25, 2022

Ribociclib Shows Favourable Immunomodulatory Effects in HR-Positive Breast Cancer

European Journal of Cancer


Additional Info

European Journal of Cancer
Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial
Eur. J. Cancer 2021 Dec 22;162(xx)45-55, CA Peuker, S Yaghobramzi, C Grunert, L Keilholz, E Gjerga, S Hennig, S Schaper, IK Na, U Keller, S Brucker, T Decker, P Fasching, T Fehm, W Janni, S Kümmel, A Schneeweiss, M Schuler, D Lüftner, A Busse

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading